The Dow fought its way higher on Wednesday as oil prices fell and positive sentiment swelled on hopes that lawmakers will soon approve a rescue plan for Fannie and Freddie.   Read More

On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."    Read More

More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.    Read More

Shares of Merck, which have lost more than a third of their value so far this year, are under continued pressure this morning. They were at 60 bucks in early January. Today they're trading around $37. Big pharma analyst Rupesh Patel at UBS is downgrading the Dow component from Buy to Neutral because he thinks it's gonna be "range-bound near-term"...    Read More

Cramer offers his plan of action to handle a 358-point decline.   Read More

The Dow closed sharply lower Friday, registering its third triple-digit loss in four sessions. What's the "Word on the Street?"   Read More

This year, for the first time ever, ASCO agreed to let CNBC broadcast live from inside McCormick Place. It took years of reasoning, pleading, nagging and complaining to get inside. But finally, ASCO consented. In the past, the scientific organization has tried to keep more than an arm's distance from the financial media.   Read More

Up until last month, AMGN had been atop the list of pharmaceutical manufacturer donors and PFE was in a close second. But the CRP says they flip-flopped in the most recent month that figures are available. So far, in the 2008 election cycle, Pfizer's given $862,000 to candidates and Amgen has forked over $852,000.    Read More

Traders will be glued to the web Thursday night as thousands of cancer studies go online. What’s the trade as these studies potentially send shock waves through biotech stocks on Friday morning?   Read More

I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.    Read More